{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-053387","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.041029+00:00","generated_at":"2026-06-16T05:19:00.488991+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Priveterra amends AEON Biopharma merger: lower cash condition, extended termination, new sponsor vesting terms","bullets":["Minimum cash condition reduced from $45M to $40M; expense cap increased to $10.3M.","70% of founder shares (4.83M) become contingent, vesting based on $5.00 avg price or forfeited.","Termination date extended to July 21, 2023; board set at 5 directors (2 AEON, 1 SPAC, 2 independent).","Promissory note of up to $1M issued to sponsor, non-interest bearing, payable at business combination.","Outstanding AEON RSUs and options converted to combined company equity with adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-053387","json":"https://secwatch.observer/filing/0001104659-23-053387.json","markdown":"https://secwatch.observer/filing/0001104659-23-053387.md","text":"https://secwatch.observer/filing/0001104659-23-053387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/0001104659-23-053387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/tm2314221d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:19:00.488991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8acfa98cb81231ebbe07b1a879eb7295069b2bb6","claim":"AEON Biopharma, Inc. amended Amendment No. 1 to Sponsor Support Agreement with Priveterra Sponsor, LLC valued at Amendment to Sponsor Support Agreement - 70% of Founder Shares unvested and subject to forfeiture pr (effective 2023-04-27).","evidence_excerpt":"On April 27, 2023, Priveterra, the Sponsor, AEON and the other parties thereto entered into an Amendment No. 1 to the Sponsor Support Agreement (the \" SSA Amendment \").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/0001104659-23-053387-index.htm","confidence":0.85,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Priveterra Sponsor, LLC"},{"label":"Value","value":"Amendment to Sponsor Support Agreement - 70% of Founder Shares unvested and subject to forfeiture pr"},{"label":"Effective","value":"2023-04-27"}],"fact_type":"material_agreement"},{"claim_id":"ba966511c3a1722fa5e01a188826de58ecaa0c6c","claim":"AEON Biopharma, Inc. amended Amendment No. 1 to Business Combination Agreement with AEON Biopharma, Inc. valued at Amendment to Business Combination Agreement - reduced minimum cash condition from $45M to $40M, incr (effective 2023-04-27).","evidence_excerpt":"On April 27, 2023, Priveterra, AEON and Merger Sub entered into an Amendment No. 1 to the Business Combination Agreement (the \" BCA Amendment \").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/0001104659-23-053387-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"AEON Biopharma, Inc."},{"label":"Value","value":"Amendment to Business Combination Agreement - reduced minimum cash condition from $45M to $40M, incr"},{"label":"Effective","value":"2023-04-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}